San Diego, California — It's still early days, but brand-new formulations of rescue benzodiazepine could be in store for patients who have acute repetitive seizures (ARS). Promising phase 3 trial ...
A new study by Tufts University researchers found a molecule that could be a target for treatment in patients who have become resistant to traditional anti-seizure drugs Newswise — Researchers at ...
Tranquilizers work better than placebos at treating the symptoms of alcohol withdrawal syndrome but they may not work better than other drugs, according to a new review of recent studies. The class of ...
Newswise — A benzodiazepine is the first-line treatment of choice for status epilepticus. Guidelines from the Neurocritical Care Society (2012) and the American Epilepsy Society (2016) recommend ...
Raanana, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the launch of preclinical studies for an intranasal delivery system for Benzodiazepines, aiming to improve treatment options ...
Among outpatients who were screened for alcohol use, those with unhealthy alcohol use, women, and those who were older, white, and of lower socioeconomic status were more likely to use benzodiazepines ...
There are three treatment options commonly used by doctors in the emergency room to treat patients with refractory status epilepticus, severe seizures that continue even after benzodiazepine ...
Researchers at Tufts University School of Medicine and colleagues have identified a small molecule that may help treat people with epilepsy whose condition has become resistant to the benzodiazepine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results